Agios Pharmaceuticals, Inc. (AGIO) EPS Estimated At $-1.62

July 14, 2018 - By Tamara Reed

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) LogoInvestors sentiment increased to 1.72 in Q1 2018. Its up 0.50, from 1.22 in 2017Q4. It is positive, as 13 investors sold Agios Pharmaceuticals, Inc. shares while 44 reduced holdings. 35 funds opened positions while 63 raised stakes. 52.93 million shares or 15.82% more from 45.70 million shares in 2017Q4 were reported.
Voya Investment Mgmt Limited Liability Corp holds 0% or 17,525 shares. Bancshares Of Montreal Can has invested 0% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Dimensional Fund Advsr L P, a Texas-based fund reported 76,644 shares. Credit Suisse Ag holds 0% or 44,671 shares in its portfolio. Goldman Sachs Gru Inc has 1.15M shares for 0.02% of their portfolio. Moreover, Verition Fund Management Ltd Liability Corp has 0.05% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Opus Point Prtn Mgmt Ltd Liability reported 16,002 shares or 2.57% of all its holdings. Bnp Paribas Asset Mngmt Holding Sa accumulated 167,691 shares. Partner Inv Mngmt Ltd Partnership accumulated 7,821 shares. Art Limited Liability Company owns 7,887 shares. World invested 0.01% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Price T Rowe Assoc Inc Md has invested 0.04% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Eventide Asset Mgmt Ltd Liability Com has invested 0.68% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Btg Pactual Glob Asset Mngmt Ltd owns 0.18% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 7,979 shares. Envestnet Asset invested in 262 shares.

Since January 16, 2018, it had 1 buying transaction, and 32 sales for $31.33 million activity. $225,607 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) shares were sold by Biller Scott. Another trade for 13,000 shares valued at $1.24M was sold by Schenkein David P. On Wednesday, March 14 Bowden Christopher sold $164,661 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) or 2,000 shares. Alenson Carman sold $23,104 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) on Monday, July 9. Foster-Cheek Kaye I sold $557,396 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) on Monday, March 19. Scadden David bought $16,688 worth of stock or 200 shares.

Analysts expect Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) to report $-1.62 EPS on August, 14.They anticipate $0.16 EPS change or 8.99 % from last quarter’s $-1.78 EPS. After having $-1.63 EPS previously, Agios Pharmaceuticals, Inc.’s analysts see -0.61 % EPS growth. The stock decreased 0.09% or $0.08 during the last trading session, reaching $90.4. About 158,829 shares traded. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has risen 88.28% since July 14, 2017 and is uptrending. It has outperformed by 75.71% the S&P500.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Ratings Coverage

Among 7 analysts covering Agios Pharma (NASDAQ:AGIO), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Agios Pharma had 8 analyst reports since February 14, 2018 according to SRatingsIntel. The rating was initiated by Oppenheimer on Monday, June 18 with “Hold”. On Wednesday, February 14 the stock rating was maintained by RBC Capital Markets with “Buy”. The firm has “Overweight” rating by JP Morgan given on Thursday, February 15. The firm has “Outperform” rating given on Wednesday, April 11 by Credit Suisse. The rating was maintained by Credit Suisse with “Buy” on Thursday, February 15. The rating was initiated by Piper Jaffray on Wednesday, May 30 with “Buy”.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The company has market cap of $5.21 billion. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. It currently has negative earnings. The firm is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients.

More notable recent Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) news were published by: Seekingalpha.com which released: “Week In Review: CStone Acquires China Rights To Leukemia Drug In $424 Million Deal” on July 01, 2018, also Nasdaq.com with their article: “Agios Announces Initiation of Global Phase 3 Trial (ACTIVATE) of AG-348 in Adults with Pyruvate Kinase Deficiency …” published on June 18, 2018, Nasdaq.com published: “Analysis: Positioning to Benefit within Biglari, Trustmark, Allscripts Healthcare Solutions, Agios Pharmaceuticals …” on June 29, 2018. More interesting news about Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) were released by: Nasdaq.com and their article: “Agios and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and …” published on June 26, 2018 as well as Benzinga.com‘s news article titled: “Benzinga’s Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street” with publication date: June 21, 2018.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: